R.a. Session II - 12 Jul 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Reporting relationship: 10%+ Owner
Issuer ticker: TSHA
Reported as of: 12 Jul 2023
Net transaction value: -$60,771
SEC form: 4
Accepted by SEC: 14 Jul 2023, 16:00:39 UTC
Prior SEC filing: 26 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ R.A. Session II

Key filing fact

R.a. Session II filed Form 4 for Taysha Gene Therapies, Inc. (TSHA) on 14 Jul 2023.

Key facts

This page summarizes R.a. Session II's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Jul 2023, 16:00.

Change

Previous filing in this sequence was filed on 26 Jun 2023.
Current net transaction value: -$60,771.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSHA transaction

Common Stock

Sale

Transaction value: $57,030
Shares: -80,528
Change %: -0.9%
Price: $0.7082
Shares after: 8,877,091
Date: 12 Jul 2023
Ownership: Direct
Footnotes: F1

TSHA transaction

Common Stock

Sale

Transaction value: $3,741
Shares: -5,344
Change %: -0.06%
Price: $0.7000
Shares after: 8,871,747
Date: 13 Jul 2023
Ownership: Direct

TSHA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 141,090
Date: 12 Jul 2023
Ownership: See footnote
Footnotes: F2

TSHA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 141,090
Date: 12 Jul 2023
Ownership: See footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.

Footnote F3

The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.